JPMorgan initiated coverage of BillionToOne (BLLN) with an Overweight rating and $150 price target BillionToOne is a molecular diagnostics company that leverages proprietary single molecule next-generation sequencing technology used in prenatal and oncology testing, the analyst tells investors in a research note. The firm likes the setup for the stock, saying the company will continue to build out its commercial infrastructure to capture growing demand in both prenatal and oncology.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN:
- BillionToOne initiated with a Hold at Jefferies
- BillionToOne, Inc.: Strong Market Position and Profitability Justify Buy Rating
- BillionToOne’s Innovative Platform Poised for Growth in Reproductive Health and Oncology Markets
- BillionToOne’s Innovative Sequencing Platform and Strong Growth Prospects Justify Buy Rating and $150 Price Target
- Balanced Outlook on BillionToOne, Inc.: High Growth Potential Amidst Competitive Challenges